Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients

Transfusion

Volumn 53, Issue 8, 2013, Pages 1722-1729

  Keshtkaran, Ali ^a   Javanbakht, Mehdi ^a   Salavati, Sedigheh ^a   Mashayekhi, Atefeh ^a   Karimi, Mehran ^a   Nuri, Bijan ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE;

ADULT; ARTICLE; BETA THALASSEMIA; COST UTILITY ANALYSIS; CROSS-SECTIONAL STUDY; DRUG ADMINISTRATION ROUTE; DRUG COST; FEMALE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; QUALITY ADJUSTED LIFE YEAR; RECOMMENDED DRUG DOSE; TRANSFUSION;

ADMINISTRATION, ORAL; ADULT; BENZOATES; BETA-THALASSEMIA; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DEFEROXAMINE; DRUG COSTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; IRAN; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84882452043     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12024     Document Type: Article

References (34)

1. Fucharoen S, Winichagoon P,. Haemoglobinopathies in southeast Asia. Indian J Med Res 2011; 134: 498-506.
2. Weatherall DJ,. The challenge of thalassemia for the developing countries. In:, Vichinsky EP, editor. Cooley's anemia eighth symposium. Ann NY Acad Sci 2005; 1054: 11-17.
3. Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P,. Inherited disorders of hemoglobin. In:, Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease control priorities in developing countries. New York: Oxford University Press; 2006. p. 663-680.
4. Weatherall DJ,. The challenge of haemoglobinopathies in resource-poor countries. Br J Haematol 2011; 154: 736-744.
5. Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, Ehsani MA, Najmabadi H, Akbari MT, Afrasiabi A, Akhavan-Niaki H, Hoorfar H,. Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol 2007; 29: 233-238.
6. Rahimi Z, Muniz A, Akramipour R, Tofieghzadeh F, Mozafari H, Vaisi-Raygani A, Parsian A,. Haplotype analysis of beta thalassemia patients in Western Iran. Blood Cells Mol Dis 2009; 42: 140-143.
7. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Alberti D, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-3462.
8. Goldberg SL,. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leuk Res 2007; 31 Suppl 3: S16-22.
9. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A,. Survival and complications in thalassemia. Ann N Y Acad Sci 2005; 1054: 40-47.
10. Kim J, Kim Y,. A time-cost augmented economic evaluation of oral deferasirox versus infusional dereroxmine for patients with iron overload in South Korea. Value Health 2009; 12 Suppl 3: S78-81.
11. Pathare A, Taher A, Daar S,. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol 2010; 89: 405-409.
12. Miyazawa K, Ohyashiki K, Urabe A, Hata T, Nakao S, Ozawa K, Ishikawa T, Kato J, Tatsumi Y, Mori H, Kondo M, Taniguchi J, Tanii H, Rojkjaer L, Omine M,. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan. Int J Hematol 2008; 88: 73-81.
13. Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM,. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. Oncologist 2009; 14: 489-496.
14. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T,; Deferasirox in Sickle Cell Investigators. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136: 501-508.
15. Metzgeroth G, Dinter D, Schultheis B, Dorn-Beineke A, Lutz K, Leismann O, Hehlmann R, Hastka J,. Deferasirox in MDS patients with transfusion-caused iron overload-a phase-II study. Ann Hematol 2009; 88: 301-310.
16. Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, Clark J, Habr D, Porter JB,. Efficacy and safety of deferasirox doses of >30 mg/kg per day in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009; 147: 752-759.
17. Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, Fucharoen S, Cianciulli P, Grady RW, Prossomariti L, Porter JB, Iacono A, Cappellini MD, Bonifazi F, Cassarà F, Harmatz P, Wood J, Gluud C,. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis 2011; 47: 166-175.
18. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D,. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873-880.
19. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A,. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-1193.
20. Luangasanatip N, Chaiyakunapruk N, Upakdee N, Wong P,. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. Clin Drug Investig 2011; 31: 493-505.
21. Delea T, Sofrygin O, Thomas S, Baladi JF, Phatak P, Coates TD,. PHM1 cost-effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassemia patients. Value Health 2006; 9: A143.
22. Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R,. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin 2008; 24: 1609-1621.
23. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB,. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-1258.
24. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A,. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733-3737.
25. Ladis V, Chouliaras G, Berdoukas V, Moraitis P, Zannikos K, Berdoussi E, Kattamis C,. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. Eur J Haematol 2010; 85: 335-344.
26. Pourmalek F, Abolhassani F, Naghavi M, Mohammad K, Majdzadeh R, Holakouie Naeini K, Fotouhi A,. Direct estimation of life expectancy in the Islamic Republic of Iran in 2003. East Mediterr Health J 2009; 15: 76-84.
27. Chouliaras G, Yiannoutsos CT, Berdoukas V, Ladis V,. Cardiac related death in thalassaemia major: time trend and risk factors in a large Greek unit. Eur J Haematol 2009; 82: 381-387.
28. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJ, editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003. p. 329.
29. Stinnett AA, Mullahy J,. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18 (2 Suppl): S68-80.
30. Blumenschein K, Johannesson M,. Incorporating quality of life changes into economic evaluations of health care: an overview. Health Policy 1996; 36: 155-166.
31. Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD,. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients-US healthcare system perspective. Pharmacoeconomics 2007; 25: 329-342.
32. Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF,. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin Ther 2007; 29: 909-917.
33. Javanbakht M, Baradaran HR, Mashayekhi A, Haghdoost AA, Khamseh ME, Kharazmi E, Sadeghi A,. Cost-of-illness analysis of type 2 diabetes mellitus in Iran. Plos ONE 2011; 6: e26864.
34. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A,. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010; 115: 2364-2371.